What is StemoniX?
StemoniX is at the forefront of neurotechnology, developing sophisticated engineered human brain models that accurately replicate complex neurological functions, including memory, learning, and cognition. Their proprietary CNS-3D and PNS-3D technologies, integrated with advanced tissue engineering, neural interfacing, and artificial intelligence, offer researchers and developers unprecedented tools for neuroscience exploration, accelerated drug discovery, and the advancement of neurological therapies. The company's focus on creating functional brain models positions it as a key player in the rapidly evolving biotech and neurotech sectors.
How much funding has StemoniX raised?
StemoniX has raised a total of $23.3M across 4 funding rounds:
Angel/Seed
$2.5M
Series A
$6M
Series B
$14.4M
Debt
$350K
Angel/Seed (2016): $2.5M, investors not publicly disclosed
Series A (2017): $6M led by Exponential.io
Series B (2019): $14.4M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Key Investors in StemoniX
Exponential.io
Exponential.io is a software industry entity that likely provides technological infrastructure or support, potentially focusing on data analytics or platform development relevant to StemoniX's AI and neural interfacing technologies.
What's next for StemoniX?
With its recent major strategic investment and substantial total funding, StemoniX is poised for significant expansion. The enterprise-level capital infusion is expected to fuel further research and development, enhance its technological capabilities, and broaden its market reach. This strategic backing will likely enable StemoniX to scale its operations, refine its neurotechnology platforms, and potentially forge new partnerships within the pharmaceutical and biotechnology industries, accelerating the path to clinical applications and commercialization of its innovative brain models.
See full StemoniX company page
